

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/835,996	04/16/2001	Dennis G. Ballinger	28110/35915A	6033	
75	7590 03/18/2004		EXAMINER		
	LI-HSIEN RIN-LAURES			TUNG, JOYCE	
HYSEQ, INC. 670 ALMANOR AVENUE			ART UNIT	PAPER NUMBER	
SUNNYVALE,	SUNNYVALE, CA 94085			1637	

DATE MAILED: 03/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

м. на	Application No.	Applicant(s)				
	09/835,996	BALLINGER ET AL.				
Office Action Summary	Examiner	Art Unit				
,		1637				
The MAILING DATE of this communicate	Joyce Tung					
Period for Reply	аррошо он ало осто отости					
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA - Extensions of time may be available under the provisions of 3' after SIX (6) MONTHS from the mailing date of this communic - If the period for reply specified above is less than thirty (30) da - If NO period for reply is specified above, the maximum statuto - Failure to reply within the set or extended period for reply will, Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	ATION. 7 CFR 1.136(a). In no event, however, may a relation. ays, a reply within the statutory minimum of third by period will apply and will expire SIX (6) MON by statute, cause the application to become AE	reply be timely filed ty (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed c	on 30 December 2003.					
	☐ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
						Disposition of Claims
4)⊠ Claim(s) <u>10-12</u> is/are pending in the ap	plication.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	·					
6)⊠ Claim(s) <u>1012</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction	n and/or election requirement.					
Application Papers						
9)☐ The specification is objected to by the E	xaminer.					
· · · · · · · · · · · · · · · · · · ·	☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the	e correction is required if the drawing	(s) is objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by	the Examiner. Note the attached	d Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International * See the attached detailed Office action for	cuments have been received. cuments have been received in A he priority documents have been Bureau (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s)	A) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Summan /DTO 4123				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO- 	-948) Paper No(s	Summary (PTO-413) s)/Mail Date				
3) Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date <u>03212002</u> .		nformal Patent Application (PTO-152)				

Application/Control Number: 09/835,996

Art Unit: 1637

DETAILED ACTION

Following the entry of the amendment filed 12/30/2003, the claims 10-12 are pending.

Election/Restrictions

1. Applicant's election with traverse of Group III, claims 10-12 in Paper No. 12302003 is acknowledged. The traversal is on the ground(s) that Groups I-III should be examined simultaneously. However, Groups I-II, claims 1-9 and Groups IV-IX, claims 13-20 were canceled. The arguments are moot.

The requirement is still deemed proper and is therefore made FINAL.

Specification

2. The title of the invention is not descriptive because the instant claims are drawn to a polypeptide amino acid sequence. A new title is required that is clearly indicative of the invention to which the claims are directed.

Claim Rejections - 35 USC § 101

3. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 10-12 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

As disclosed in the specification, there are multiple utilities listed for the proteins of the instant invention comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43 or 45, for example, apoprotein, lipase or lipoprotein receptor activity (See pg. 33, lines 9-14 and pg. 65, lines 14-31 of the specification).

Art Unit: 1637

However, the specification does not disclose a specific utility for the polypeptide comprising SEQ ID NO: 27.

4. Claims 10-12 is also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 11-12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification disclose four variant nucleotide sequences set forth in SEQ ID NO: 22, 24, 26 and 44 and their respective deduced amino acid sequences set forth in SEQ ID NO: 23, 25, 27, and 45 in which the polypeptide amino acid sequence, SEQ ID NO: 27 is encoded by the nucleic acid sequence, SEQ ID NO: 26 (See pg. 48 of the Sequence Listing). There is no further descriptions of the variants provided regarding one or more amino acid substitutions, deletions, insertions and/or additions of a polypeptide amino acid sequence to have the polypeptide having

Application/Control Number: 09/835,996

Art Unit: 1637

Page 4

greater than about 90% sequence identity with the polypeptide amino acid, SEQ ID NO: 27.

Thus, one of skill in the art would conclude that applicant was not in possession of the claimed genus because a description of only one member of this genus is not representative of the

Summary

variants of the genus and is insufficient to support the claim.

7. No claims are allowed.

8. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

9. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung J A March 11, 2004

> ETHAN WHISENANT PRIMARY EXAMINER